Is It Too Late to Buy Eli Lilly? Billionaire Ken Griffin Doesn't Think So. He Nearly Quadrupled His Stake in the Pharma Stock in Q2.
Eli Lilly looks like a strong long-term investment thanks to its booming obesity drugs and Alzheimer's treatment, and to Billionaire Ken Griffin's investment.
Overview
In the second quarter of this year, Ken Griffin nearly quadrupled Citadel's stake in Eli Lilly (NYSE: LLY), adding around 740,000 shares and making it one of his fund's top positions. A billionaire who can buy almost anything chose to lean into this pharma stock. I think that matters.
Griffin is backing a company that sits at the center of two of the biggest medical shifts of this decade: obesity and Alzheimer's disease.
Details
On the obesity side, Lilly's incretin drugs Mounjaro and Zepbound have turned into a franchise that is changing how doctors treat weight and diabetes. In the second quarter of 2026, Eli Lilly reported revenue of about $23.0 billion, up 48% year over year, driven mainly by volume growth in Mounjaro and Zepbound. Mounjaro alone brought in roughly $9.9 billion in sales, with Zepbound adding another $4.9 billion as demand grew across the United States and abroad.
Source
Originally published at www.fool.com.